Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a Open-label Clinical Trial Evaluating VBC108, a CLDN18.2 and CDH17-directed Bi-specific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors

NCT07700160 is registered in ClinicalTrials.gov with VelaVigo Bio Inc as lead sponsor.

NCT NCT07700160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07700160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a Open-label Clinical Trial Evaluating VBC108, a CLDN18.2 and CDH17-directed Bi-specific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors
Lead sponsor
VelaVigo Bio Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 30, 2026
Completion date
September 17, 2029
Enrollment
230 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors